Adynxx’s pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain. Adynxx is collaborating with twoXAR to use twoXAR’s artificial intelligence-driven drug discovery platform to identify endometriosis treatments. Adynxx is also actively evaluating in-licensing opportunities with transformative therapeutic profiles to treat pain and inflammation.
The AYX therapeutic approach
The AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. AYX decoys are short DNA molecules, or oligonucleotides, that selectively inhibit transcription factors controlling the genes involved in the maintenance of pain. As a result, a single administration of an AYX decoy produces a robust, long-term reduction of pain and associated clinical benefits.
Brivoligide (AYX1) for the prevention of post-surgical pain
A potent and selective inhibitor of the transcription factor EGR1, brivoligide addresses a specific physiology of pain associated with poor post-surgical outcomes in patients identified using the Pain Catastrophizing Scale. Clinical studies suggest that a single preoperative administration of brivoligide safely reduces pain for weeks, accelerates the time to achieve mild pain, and substantially reduces the need for opioid use during recovery.
AYX2 for the long-term suppression of chronic pain
AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) 6, 9 and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 produces a robust and long-lasting suppression of inflammatory and neuropathic chronic pain. By addressing the genomic roots of chronic pain, AYX2 may suppress it without the side-effects and abuse potential of standard-of-care. AYX2 is in pre-clinical development.
AI-based platforms, such as twoXAR’s, are helping create portfolios of drug programs more efficiently through faster, more predictive models than traditional approaches. Adynxx is seeking to identify product candidates with the potential to address the core mechanisms of endometriosis and significantly differentiate from standard of care, using twoXAR’s proprietary AI-driven platform.